Table 3.
Demographic and clinical characteristics of participants evaluated in the Sleep and Asthma Cohort (SAC) Study and the pediatric component of the Cooperative Study of Sickle Cell Disease (CSSCD) cohort.
| Characteristic | SAC Study (n=159) | CSSCD (n=243) |
|---|---|---|
| Sex, n (% Males) | 82 (51.6) | 125 (51.4) |
| Age of first contact (yrs.)§ | 9.00 (6.0) | 0.23 (0.19) |
| Prospective Follow-up* (yrs.) § | 5.23 (1.71) | 8.93 (4.65) |
| Pain rate, lifetime (events/patient year)§ | 0.37 (0.70) | 0.35 (0.79) |
| Pain rate, prospective (events/patient year)§ | 0.46 (1.17) | 0.40 (0.89) |
| Pain event before age 4, n (%) | 84 (52.8) | 103 (42.4) |
| ACS rate, lifetime (events/patient year)§ | 0.14 (0.32) | 0.14 (0.34) |
| ACS rate, prospective (events/patient year)§ | 0.16 (0.35) | 0.12 (0.32) |
| ACS event before age 4, n (%) | 38.4% | 48% |
| Hemoglobin (g/dl)# | 8.25 ± 1.20 | 8.60 ± 1.00 |
| White Blood Cells, 109/L# | 12.12 ± 3.88 | 12.70 ± 2.75 |
| Mother has asthma, n (%) | 21 (13.2) | 17 (9.1) |
| Wheezing causing shortness of breath, n (%) | 42 (26.4) | Not Evaluated |
| Wheezing after playing hard, n (%) | 53 (33.3) | Not Evaluated |
| Wheezing without having a cold, n (%) | 33 (20.8) | Not Evaluated |
| Cough without having a cold, n (%) | 60 (37.7) | Not Evaluated |
| Congested or phlegm without a cold, n (%) | 22 (13.8) | Not Evaluated |
| Two or more positive skin tests, n (%)** | 38 (27.0) | Not Evaluated |
| Bronchodilator response ≥ 12%, n (%)** | 31 (21.5) | Not Evaluated |
| Lower airway obstruction, n (%)** | 28 (19.4) | Not Evaluated |
Prospective follow-up is from date of entry in SAC and from the age of 4 in CSSCD; Minimum follow-up of three years
Mean (std dev.) for continuous variables with a normal distribution
Median (IQR) for continuous variables with a non-normal distribution
141 patients with non-missing data in SAC for skin tests, 144 patients with non-missing data in SAC for bronchodilator response, and 144 patients with non-missing data in SAC for lower airway obstruction, defined as the forced expired volume in 1 second/forced vital capacity (FEV1/FVC) < lower limit of normal (LLN) according these equations provided by Quanjer et al11.